Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000363

Drug Information
NameValsartan
SynonymsL-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-; C081489; Spectrum4_000749; (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid; SMR000466318; CGP 48933; CID60846; CHEMBL1069; Spectrum_001796; MLS001424088; DB00177; (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid; |Tareg; Kalpress; C24H29N5O3; KBio2_004855; UNII-80M03YXJ7I; KBio2_002287; Bio-0796; L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-; BSPBio_003501; L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI); N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine; Sanol brand of valsartan; BIDD:GT0345; BRD-K45158365-001-02-3; AC1L1U1M; D00400; KBio3_003006; Miten; Spectrum2_001120; Valsartan (JAN/USAN/INN); MLS000759423; (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine; MolPort-003-666-608; Diovan; SAM001246581; Nisis||; Diovan, Valsartan; AC-4543; Spectrum3_001831; CEPA brand of valsartan; HMS1922L21; Valsarran; Esteve brand of valsartan; KBioGR_001078; HMS2051L12; KBioSS_002289; CPD000466318; Vals; N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine; Spectrum5_001582; Novartis brand of valsartan; HMS2093K22; MolPort-002-507-854; Valsartan [USAN:INN]; CGP-48933; SPBio_001260; TL8000869; Aventis brand of valsartan; HSDB 7519; CHEBI:9927; AC1Q5QIK; S1894_Selleck; Lacer brand of valsartan; (s)-3-methyl-2-(pentanoyl-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino)-butyric acid 137862-53-; KBio2_007423; N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine; Diovan (TN); SPECTRUM1505209; valsartan; N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine; 137862-53-4; Schwarz brand of valsartan; Ambap137862-53-4; LS-161334; N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine; Provas; Tareg; Nisis; walsartan
Trade NameDiovan; Valtan; Valzaar
CompanyNorvatis Phamaceuticals Corporation
IndicationHypertension
[ICD9: 401   ICD10: I10, I11, I12, I13, I15]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-1
8(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4
-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1
InChIKeyACWBQPMHZXGDFX-QFIPXVFZSA-N
Canonical SMILESCCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O    
Isomeric SMILESCCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O
Therapeutic ClassAntihypertensive Agents
CAS NumberCAS 137862-53-4
FormulaC24H29N5O3
PubChem Compound IDCID 60846.
PubChem Substance IDSID 197083.
ChEBI9927;
SuperDrug ATC IDC09CA03
SuperDrug CAS ID137862534;
TargetType-1 angiotensin II receptorAntagonist[2][3]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41. To Reference
Ref 3Nat Rev Drug Discov. 2003 Jan;2(1):38-51.Knockouts model the 100 best-selling drugs--will they model the next 100? To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543